Related Experiment Video
Updated: Aug 25, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
Philip T Sobash1, Asad Ullah2, Nagla Abdel Karim3
1Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.
Abstract:
Pulmonary carcinoid tumors are a rare subtype of neuroendocrine cell tumor found in approximately 1-2% of lung cancers. Management is primarily through surgical resection, with limited benefit of adjuvant therapy in the clinical setting. Genomic profiling is in the nascent stages to molecularly classify these tumors, but there are promising insights for future targeted therapy. A total of 80 abstracts were analyzed for further review with 11 included in our final analysis. Only 4 of the 11 reviewed in depth provided statistical analysis. We evaluated PFS, OS, 1- and 5-year survival as mentioned in the studies. Nodal and KI67 status were also analyzed. Based on the current literature, there is no definitive evidence that adjuvant chemotherapy after resection confers a survival benefit in typical or atypical carcinoids.
Insights
Adjuvant chemotherapy offers no survival benefit for typical or atypical pulmonary carcinoid tumors after surgical resection. Further research is needed to explore targeted therapies based on genomic profiling.
Area of Science:
- Oncology
- Pulmonary Medicine
- Cancer Research
Background:
- Pulmonary carcinoid tumors are rare neuroendocrine lung cancers, comprising 1-2% of all lung malignancies.
- Current management relies on surgical resection, with limited evidence supporting adjuvant therapies.
Purpose of the Study:
- To review the existing literature on the efficacy of adjuvant therapy for pulmonary carcinoid tumors.
- To assess the impact of adjuvant chemotherapy on survival outcomes and relevant prognostic factors.
Main Methods:
- A systematic review of 80 abstracts was conducted, with 11 studies included in the final analysis.
- Statistical data on progression-free survival (PFS), overall survival (OS), 1- and 5-year survival rates were evaluated.
- Nodal status and KI67 proliferation index were also analyzed.
Main Results:
- Only 4 of the 11 reviewed studies provided statistical analysis.
- The analysis found no definitive evidence supporting a survival benefit from adjuvant chemotherapy in typical or atypical pulmonary carcinoids post-resection.
Conclusions:
- Current literature does not support the routine use of adjuvant chemotherapy after surgical resection for pulmonary carcinoid tumors.
- Genomic profiling shows promise for future targeted therapy development in these rare neuroendocrine tumors.
More Related Videos
Related Concept Videos
01:21Cancer Survival Analysis
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers